Cagent Vascular launches Serranator SL-PRO for CLTI and pedal disease

271
Michael Lichtenberg

Cagent Vascular has announced the launch of the Serranator SL-PRO percutaneous transluminal angioplasty (PTA) serration balloon catheter for chronic limb-threatening ischaemia (CLTI) and pedal disease.

A press release notes that Serranator SL-PRO utilises Cagent’s proven serration technology on a redesigned platform, offering improved deliverability and trackability, while offering Serranator’s proven 1,000 times increase in point force versus plain balloon. The release adds that Serranator SL-PRO’s innovative mechanism of action allows for predictable and controlled lumen gain with minimal dissection.

Michael Lichtenberg (Arnsberg Clinic, Arnsberg, Germany) commented: “As an experienced Serranator operator, my team has grown accustomed to the benefits of serration, including great lumen gain, low complication rate, and low 6% BTK [below-the-knee] vessel recoil vs. 55% measured recoil with plain balloon.”

Lichtenberg continued: “We also appreciate Serranator’s ability to safely and effectively treat complex disease, even down into the pedal arteries. With SL-PRO, we’re eager to experience the advantages of serranation in this new, more deliverable platform.”

Cagent Vascular chairman and chief executive officer Brian Walsh added: “We are committed to consistently developing and advancing solutions for physicians treating PAD [peripheral arterial disease] patients, and winning the fight against this debilitating disease. With over 20,000 procedures now completed and a growing library of clinical data, Serranator has proven itself to be a valuable tool in this fight. The Serranator SL-PRO is a purpose-built tool for pedal intervention, and with it, the Serranator product family can now treat from hip to toe.”

Cagent Vascular advises that the Serranator and Serranator SL-PRO PTA serration balloon catheters are US Food and Drug Administration (FDA)-cleared, novel balloons using proprietary stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. “With 1,000x more point force compared with plain balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies,” the company explains.


LEAVE A REPLY

Please enter your comment!
Please enter your name here